Background: Disease status before high-dose chemotherapy with autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) is an important predictor of transplantation-related toxicity and event-free survival (EFS) for patients with relapsed or refractory Hodgkin's disease (HD). We performed a phase II study in patients with relapsed or refractory HD to evaluate the feasibility of four cycles of Dexa-BEAM followed by highdose chemotherapy with ABMT or PBSCT.
Introduction
Patients with Hodgkin's disease (HD) who have primary refractory disease or who relapse after attaining a complete response with chemotherapy and/or radiotherapy are rarely cured with conventional chemotherapy [1] [2] [3] [4] . The long-term follow-up of patients treated with aggressive salvage chemotherapies showed a survival rate of 24% for patients with long (> 12 months) initial remission and less than 12% for patients with short (<12 months) initial remission [1] . High-dose chemotherapy and autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBSCT) are being increasingly employed in the management of patients with relapsed or refractory HD. High-dose chemotherapy has been shown to produce long-term disease-free survival (DFS) in selected patients with relapsed or advanced refractory HD. Approximately 30% to 64% DFS has been reported from several series [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] .
The most commonly used conditioning regimens are: cyclophosphamide, carmustine (BCNU) and etoposide (CVB) [18] [19] [20] or carmustine (BCNU), etoposide, cytarabine and melphalan (BEAM) [13] . Recently, excellent results were reported with the addition of cisplatin to a modified CVB regimen (CVB + P) [9] . Total body irradiation (TBI) has been utilized only in a few studies due to the fact that many Hodgkin's patients have already received thoracic irradiation by the time they have reached the transplant stage [18, 19] .
Following the initial evaluation of high-dose chemotherapy with ABMT or PBSCT subsequent studies have focused on strategies to improve initial results. In addition to the evaluation of different conditioning regimens, the identification of patients for whom this procedere is likely to be beneficial has also been very important. As shown for ABMT in non-Hodgkin's lymphoma (NHL) recently published studies showed that the disease status before high-dose chemotherapy is an important predictor of event-free survival (EFS) and transplantationrelated toxicity in patients with relapsed or refractory HD [13] [14] [15] 17] .
We report further evidence of maximal pretransplant cytoreductive salvage therapy before high-dose chemotherapy with ABMT or PBSCT for the clinical outcome in patients with relapsed or refractory HD.
Patients and methods

Patients
Eligibility criteria include age 18-55 years, histologically proven relapsed or refractory HD and Karnofsky performance status 5 70. Exclusion criteria were current uncontrolable infectious disease, active second malignancies, ventricular ejection fraction < 50%, myocardial insufficiency NYHA III or IV, pulmonary dysfunction (diffusion capacity <60%), renal dysfunction (serum creatinine > 150 mmol/1), liver dysfunction (bilirubin or transaminasen > 2-times of normal), or any other major organ dysfunction unrelated to HD.
Patient characteristics are summarized in Table 1 . Twenty-six patients (median age 30, range 20-40 years) with relapsed or resistant Hodgkin's disease entered this study. The diagnosis and histologic subtype of HD was based on biopsy results at the time of diagnosis and at the time of relapse (20 patients nodular sclerosis, six mixed cellularity at relapse). At the time of study entry three patients had stage II, 11 patients stage III and 12 patients stage IV disease. Nine patients had B symptoms, four bone marrow involvement and five lung involvement. All patients had previously received combination chemotherapy with eight or 11 drug combinations such as cyclophosphamide, vincristine, prednisone and procarbazine (COPP) alternating with doxorubicin, bleomycin, vinblastine and dacarbazine (ABCD) or cyclophosphamide, vincristine, prednisone, procarbacine alternating . Granulocyte colony-stimulating factor (Filgrastim) was administered at doses of 300 ug (< 60 kg) or 480 ug (> 60 kg) from day 9 until WBC increased about 2500/ul for three days ( Table 2 ). Dexa-BEAM was repeated every 28 days, or if absolute leucocyte count and platelet count had recovered to > 2500/ul and > 100.000 /ul, respectively. Patients were restaged after two, three or four cycles of Dexa-BEAM salvage therapy in order to assess response.
Conditioning regimen
Patients who achieved maximal response after salvage treatment were scheduled to receive high-dose chemotherapy with ABMT (eight patients) or PBCST (10 patients). The conditioning regimen used was CVB consisting of cyclophosphamide 1.5 g/m 2 on day -6 to -3, VP-16 100 mg/m 2 12q on day -6 to -3 and BCNU 100 mg/m 2 on day -6 to -4 (Table 3) .
Supportive care
Patients were hospitalized in single rooms under reverse isolation until WBC was > 2.500/ul for three consecutive days. An indwelling central venous silastic catheter was placed in all patients. All blood products were irradiated to greater than 2.500 cGy and were given to maintain a hemoglobin level >8-9 g/dl and platelet count > 30.000/ul. All patients received G-CSF (Filgrastim) 10 Hg/kg as a 24-hour i.v. infusion until WBC reached 2.500/ul for three consecutive days. Antimicrobial prophylaxis consisted of oral tnmethoprim-sulfamethoxazole, fluconazole, nystatin and tobramycin. Intravenous broad-spectrum anti- 10ug/kg -6 to -4 -6 to -4 -6 to -3 day 0 until WBC > 2500/ul for 3 days biotics. antifungal and antiviral therapy as well as parenteral hyperalimentation were used as indicated.
BM or PBSC harvest
The technique of BM harvest has been described previously [21] . Between 1992 and April 1993 bone marrow was harvested under general anesthesia. Bone marrow harvest was performed after one or two cycles of Dexa-BEAM. Since April 1993 peripheral blood progenitor cells were collected by means of apheresis (Baxter CS 3000 Blood Cell Seperator). PBSC harvests were steady state mobilized with 10 ug/kg G-CSF after two cycles of Dexa-BEAM. Bone marrow as well as peripheral blood progenitor cells were frozen at a controlled rate, freezing 1 °C/min, in 10% dimethylsulfoxide (DMSO) and autologous plasma [22] , The cryopreserved cells were stored in the vapor phase of liquid nitrogen. Surface phenotype analysis using flow cytometry was performed as previously reported [34] , Mononuclear cells were stained with fluorescin isothiocyanate (FITC)-and phycoerythin (PE)-conjugated CD34 (anti-HPCA-2) monoclonal antibodies with mouse IgG as negative control. More than 20000 cells were analyzed with flow cytometry using a FACScan flow cytometer (Becton Dickinson) with Lysis II software. The frequency of colony-forming hematopoetic progenitor cells was evaluated as previously described [35] . Abbreviations: CR -complete remission; PR -partial remission, PD -progressive disease.
Response criteria/toxicity
A complete response (CR) was defined as the disappearence of all clinical and radiographic evidence of disease for at least three months. Partial response (PR) was defined as a greater than 50% reduction in the surface area of measurable disease. Any response less than PR, including response >50%, but lasting <1 month, was considered as treatment failure. Toxicity was evaluated according to standard World Health Organisation (WHO) criteria.
Statistical analysis
Demographics and disease characteristics were summarized using descriptive statistics. A progression-free survival curve was estimated according to the method of Kaplan and Meier.
Results
Response to salvage treatment
Results are summarized in Table 4 . Overall, 18 patients responded to Dexa-BEAM, including 16 CR and 2 PR. These 18 patients subsequently underwent high-dose chemotherapy followed by ABMT or PBSCT. Maximal response was observed after two cycles (one patient), three cycles (two patients) or four cycles (15 patients) of Dexa-BEAM. Eight patients had progressive disease. Figure 1 shows the progression-free survival for all patients (« = 26)
Toxicity of Dexa-BEAM
A total of 94 courses was administered to 26 patients, with a median number of 3.7 courses per patient (range 2-4). Seventy-eight courses were given within a 28-day cycle. All cycles could be administered at the calculated full dose. The main toxicity of Dexa-BEAM was myelosuppression with WBC of less than 1000/ul (duration 4-11 days, median 6.5 days) and thrombocytopenia of less than 25.000/ul (6-19 days, median 9.6 days) in all courses. Ninty-two platelet tranfusions were given in 78 courses (median 1.2). In 36 courses 22 patients developed fever (duration 1-9 days, median 5.2 days) requiring i.v. antibiotics for a median of 10.1 days. Moderate nausea and/or vomiting (WHO grade 1-2) was present in 19 patients (20 courses). Mild mucositis, diarrhoea and obstipation occurred in five, seven and four patients, respectively. There were no neurologic, liver or renal toxicities. All patients had complete alopecia (Table 5) . One patient died due to a gram-negative sepsis during granulocytopenia with progressive disease after four cycles of Dexa-BEAM.
Toxicity of CVB
All patients developed severe marrow aplasia WHO grade 4 after CVB. Neutropenic fever occurred in 55% of all patients for a median of three days (range 1-6 days). All of them received broad-spectrum antibiotics. Moderate nausea and/or vomiting (WHO grade 1-2) was present in all patients. Mild diarrhoea occurred in four patients. There was no treatment-related death (Table 6 ). 
Hematologic recovery after ABMT or PBSCT
The median number of bone marrow MNC harvested was 5. /kg CD34+ cells (three patients ABM, two patients PBSC) were in second or later relapse and pretreated with more than two multiagent chemotherapies. There was no significant difference in the yield of bone marrow harvest after one or two courses of Dexa-BEAM. Recovery of WBC >500/ul occurred at a median of 10 days (ABM), range 7-15 days, and nine days (PBCS), range 7-10 days. Recovery of ANC > 500/ ul occured at a median of 14 days (ABM), range 9-19 days, and 10 days (PBCS), range 8-17 days. The unsupported platelet count of 30000/ul was reached at a median of 29 days, range 13-37 days (ABM) and 23 days, range 10-42 days (PBSC).
Response
Eight patients had progressive disease under salvage treatment. Four of the eight nonresponders died of progressive disease 5, 7, 8 and 19 month after entry into the Dexa-BEAM protocol.
Currently 14 of 18 patients are in continuous complete remission (cCR) with a median follow-up of 40 months (range 14-60 months). Two patients with PR after four courses of Dexa-BEAM relapsed and died three months posttransplantation. Two patients with CR after four cycles of Dexa-BEAM relapsed nine and 13 months posttransplantation (Table 8) .
Discussion
Reports on salvage regimens for patients with Hodgkin's disease (HD) relapsing after multi-agent chemotherapy generally show a poor clinical outcome, with fewer than 30% of the patients remaining durably disease free [25] [26] [27] [28] .
High-dose chemotherapy (HDCT) followed by autologous bone marrow transplantation (ABMT) or peripheral blood stem cell transplantation (PBCST) has been shown to produce 30%-65% long-term diseasefree survival in selected patients with refractory and relapsed HD [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . Although results of HDCT have generally been better than those observed after conventional-dose salvage therapy, the validity of transplant results have been questioned because of the lack of randomized trials [6] . The most compelling evidence for the superiority of high-dose therapy in relapsed HD comes by a report from the British National Lymphoma Investigation (BNLI) [29] . Patients with relapsed or refractory HD were treated with a combination of carmustine (BCNU), etoposide, cytarabine and melphalan at a conventional-dose level (mini-BEAM) or a high-dose level (BEAM) with autologous bone marrow transplantation. The actuarial three-year DFS was significantly better in patients who received high-dose chemotherapy (53% vs. 10%).
Several published studies have evaluated the importance of prognostic factors for patients with HD undergoing HDCTwith subsequent stem cell support [13] [14] [15] 17] . As shown for ABMT in non-Hodgkin's lymphoma, chemotherapy sensitivity and disease status at the time of transplant appears to be the most important prognostic factor for ABMT in HD. Gribben et al. [17] treated 44 patients with relapsed or primary refractory HD with the BEAM protocol. Thirty-eight patients responded including 34% CR and 52% PR. Seven patients received postgraft radiotherapy to sites of residual disease. Five of these patients subsequently achieved CR. On a uniand multivariate analysis, the size of tumor mass at transplant was the only significant factor of overall survival in these patients. Rapoport et al. [15] prospectively examined 100 autotransplants for HD (47 patients) and NHL (53 patients) to identify variables with prognostic significance. Minimal disease status at the time of transplant was the major predictor of improved EFS for both patients with HD and NHL. Before admission for autologous transplant the majority of patients received one or more courses of salvage therapy, followed by restaging. The three-year actuarial EFS rate for the 47 HD patients was 49%, with a median follow-up of two years. By multivariate analysis minimal disease, defined as all areas < 2 cm, was associated with improved EFS (P = 0.003) for patients with HD. The projected EFS rate for patients entering with minimal residual disease was 70% versus 15% for patients with bulky disease, defined as at least one area >2 cm. In this study, a striking difference was also seen in treatment-induced mortality between the bulky-disease and the minimal-disease group. Among patients who entered transplantation with bulky-disease the treatment-related mortality-rate was 25% compared with 5% in patients who entered with minimal disease.
Chopra et al. [13] reported data on high-dose chemotherapy and autologous bone marrow transplantation in 155 patients with relapsed or refractory HD. In this series chemosensitivity was assessed according to the response to the latest chemotherapy administered at relapse. Thirty-two patients showed no response (resistant relapse), 26 patients showed at least a 50% response (responding relapsers) and 44 patients proceeded to ABMT without receiving conventional salvage therapy (untested relapse). The actuarial overall survival at five years was 55% with a progression-free survival (PFS) of 50%. On multivariate analysis tumor mass at ABMT {P < 0.001) as well as relapse status (P -0.007) and sex {P = 0.042) were significant prognostic factors for PFS. Patients with bulk disease at the time of transplant (defined as tumor mass > 10 cm) had a PFS rate of only 13% compared with 61% in patients with tumor mass < 5 cm.
Crump et al. [14] treated 73 patients who had failed to achieve remission with front-line chemotherapy or who had relapsed with high-dose etoposide and melphalan followed by ABMT. All patients were treated with sequential salvage chemotherapy to maximum response before ABMT. Patients with clinically or radiographically documented disease progression during or after receiving different salvage regimens were ineligible for ABMT. Those with stable disease or resolution of symptoms proceeded to intensive therapy and transplant. The CR rate for all patients was 75%>. Eighty-seven percent of patients with no evidence of disease (NED) at the time of ABMT were in CR three months posttransplantation. Of the patients with nonbulky residual disease (NBRD) after salvage therapy, 75% obtained a CR in contrast to only two of six of those transplanted with bulky disease. With a median follow-up of 30 months 44% remain in continuous complete remission. Multivariate regression analysis showed that the disease status at the time of ABMT was the most important factor determining DFS: 68%) of those patients transplanted with NED versus 26 for patients with NBRD and 0% for bulky disease.
In most of the other series reported for three-drug regimens such as CVB or four drug combinations such as BEAM [8, [30] [31] [32] or CVB + P [9] , not all patients received salvage therapy or salvage chemotherapies were applied only for chemosensitivity testing and not until maximal response, and patients were not systematically restaged before ABMT. Thus, the impact of pretransplant cytoreduction on the DFS rate from these reports is hard to assess.
The favorable outcome of patients in our study who received high-dose chemotherapy after achieving CR with the Dexa-BEAM regimen confirms reports suggesting that the disease status before transplant is an important predictor of clinical outcome and transplantation-related toxicity. Most of our patients transplanted showed unfavorable prognostic factors before entering the Dexa-BEAM protocol. Twelve patients had stage IV disease at relapse, six patients had primary refractory disease and 11 patients second or subsequent relapse. Moreover, 11 patients had a short initial remission of less than 12 months. Nevertheless, with a median follow-up of 40 months, 14 of 18 patients (78%) transplanted are in continuous complete remission. Although in most of the previous studies using high-dose chemotherapy with ABMT up to 60% of relapses occurred within the first year posttranplantation, late relapses more than six years after ABMT for HD were observed [5, 8] . Thus long-term follow-up is necessary to determine the overall curability in our trial.
Based on the inverse relationship between tumor burden and curability with chemotherapy, it seems likely that attainment of a minimal disease status is important for optimal success of autologous transplantation. In 1983 Skipper reported [33] that a clinical complete remission is associated with at least a 2-3-log cell kill and results in fewer residual resistant cells than the 0.5-1-log reduction accompanying a PR [14] . Therefore, the mean value of high-dose chemotherapy with ABMT or PBSCT might be in the sucessfull eradication of minimal residual disease in patients with HD.
Patients who do not respond to salvage therapy present a difficult management decision, because they do poorly with conventional treatment and may equally do poorly with transplantation [9, 32] .
Although the number of patients in this study is small we could demonstrate:
1. The feasibility of maximal cytoreductive salvage therapy with 3-4 courses of the Dexa-BEAM regimen followed by CVB as a preparative regimen. Early or late transplantation-related toxicities were tolerable with no treatment-related deaths. 2. In addition, our data confirms previous reports that the disease status before transplant is an important predictor of clinical outcome. Prospective autotransplant patients with chemosensitive HD should be treated with salvage chemotherapies until they are as close to CR as possible. More effective pretransplant salvage therapies capaple of producing a higher CR rate may improve the clinical outcome after ABMT or PBSCT.
